Rituximab has demonstrated utility in treating other autoimmune diseases, and this phase 2, double-blind, randomized, controlled trial compared rituximab with placebo in 57 patients with primary biliary cholangitis (PBC).
A study was recently published in Efficacy and Mechanism Evaluation that investigated the potential clinical benefit of rituximab for the treatment of fatigue in primary biliary cholangitis (PBC), an autoimmune liver disease that is characterized by the loss of the intrahepatic bile ducts accompanied by progressive cholestasis. About half of patients with PBC experience fatigue.
Rituximab has demonstrated utility in treating other autoimmune diseases, and this phase 2, double-blind, randomized, controlled trial compared rituximab with placebo in 57 patients with PBC aged 18 years or older with moderate to severe fatigue as measured by a score of greater than 33 on the PBC-40 fatigue domain scale. The trial took place at a single center in the United Kingdom in Newcastle upon Tyne Hospitals National Health Service Foundation Trust.
Patients were randomized in to receive either rituximab or a placebo. Participants received 2 transfusions of rituximab (1000 mg) or placebo on days 1 and 15 of the trial and were followed up at 3-month intervals for a year following treatment.
The primary outcome measure was the PBC-40 fatigue domain evaluation at 3 months, which was assessed on an intention-to-treat basis. Although there were no serious adverse events linked to the drug, there was also no statistically significant difference in fatigue score measured at 3 months between the rituximab and placebo arms (adjusted mean difference —0.9; 95% CI, –4.6-3.1). However, the anaerobic threshold improved significantly in the rituximab arm with an adjusted mean difference at 3 months of 1.41 (95% CI, 0.03-2.80).
Overall, researchers found that rituximab is ineffective for the treatment of fatigue in patients with PBC, despite an increase in anaerobic threshold.
Reference
Khanna A, Jopson L, Howel D, et al. Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary cirrhosis): a randomized controlled trial. [Published online April 2018]. EME. PMID: 29733563.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Survey Finds Korean Oncologists Trust Biosimilars But Prescribe Originators More
May 13th 2024A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, they often prescribe the originators due to factors like lack of patient trust in biosimilars and lower than expected cost savings.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.